SPOTLIGHT: Wyeth in licensing deal


Wyeth could gain up to $5 million through next year in a licensing deal with Novavax covering its virus-like particle technology for use in vaccine development. The technology creates viruses that mimic the disease-causing virus but lacks genetic material needed to make it a threat. Release

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.